Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)

Authors
Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2015
This article has no abstract
Epistemonikos ID: 4bd1402f3dde83b04afda0fdf8764bdb38c48e8b
First added on: Feb 07, 2025